Item 5.07 Submission of Matters to a Vote of Security Holders.
Acorda Therapeutics, Inc. (the "Company") held its Annual Meeting of
Stockholders on June 2, 2021 (the "Annual Meeting") at the Hilton Garden Inn,
201 Ogden Avenue, Dobbs Ferry, NY 10522. 5,855,590 shares of the Company's
common stock, or 61.70% of the shares of the Company's common stock issued and
outstanding on the record date for the Annual Meeting, were present in person or
represented by proxy at the Annual Meeting. Summarized below are descriptions of
the proposals voted on at the Annual Meeting and the final results of such
voting:
Proposal One: Election of directors
As described in the Company's 2021 Proxy Statement, the Company's Board of
Directors nominated two individuals to serve as Class I directors for a term to
expire on the date of the Company's 2024 Annual Meeting of Stockholders or until
their successors are duly elected and qualified. Both of such nominees were
elected by a plurality vote in accordance with the Company's Bylaws, as follows:
Director Votes For Votes Withheld Broker Non-Votes
Barry Greene 1,381,262 1,992,132 2,482,196
Catherine D. Strader, Ph.D. 2,984,507 388,887 2,482,196
Because the votes withheld from Mr. Greene exceeded the votes cast in favor of
his election, Mr. Greene has tendered his resignation for the Board's
consideration in accordance with the majority vote provision of the Company's
Bylaws. Under the procedures set forth in the Company's Bylaws, the Nominations
and Governance Committee of the Board will consider the resignation and make a
recommendation to the Board, which will determine whether to accept or reject
the resignation (and, if applicable, the reasons for rejecting the resignation)
within 90 days after the date of the Annual Meeting. Mr. Greene will not
participate in the deliberations of the Nominations and Governance Committee or
the Board with respect to their consideration of his resignation. The Company
will disclose the Board's decision-making process and decision regarding whether
to accept Mr. Greene's resignation (and the reasons for rejecting a resignation,
if applicable) in a Current Report on Form 8-K filed with the Securities and
Exchange Commission, promptly following such decision.
Proposal Two: Ratification of appointment of independent auditors
The Company's stockholders ratified the appointment of Ernst & Young LLP as the
Company's independent auditors for the fiscal year ending December 31, 2021, by
the following vote:
Votes For Votes Against Abstentions
5,712,617 109,549 33,424
Proposal Three: Advisory vote to approve named executive officer compensation
The Company's stockholders voted, in an advisory, non-binding manner, to approve
the compensation of the Company's Named Executive Officers as disclosed in the
Company's 2021 Proxy Statement pursuant to the compensation disclosure rules of
the Securities and Exchange Commission, including the Compensation Discussion
and Analysis, the executive compensation tables and the related footnotes and
narrative accompanying the tables (the "say-on-pay vote"). The Company's
stockholders voted as follows to approve such executive compensation pursuant to
the say-on-pay vote:
Votes For Votes Against Abstentions Broker Non-Votes
3,083,087 256,247 34,060 2,482,196
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ACORDA THERAPEUTICS, INC. 
